secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2026-10-05T13:20:12+00:00
Accession:  0001213900-26-106677
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

NeuroOne preliminarily reports FY2026 revenue of $10.5M and record $4.5M purchase order
--------------------------------------------------------------------------------

- Preliminary FY2026 revenue was approximately $10.5 million, at the top of guidance range of $9.2 million to $10.5 million, up 15.6% year-over-year.
- Preliminary fiscal Q4 2026 product revenue was approximately $3.8 million, up 38.4% from approximately $2.7 million in Q4 fiscal 2025.
- NeuroOne received a record $4.5 million purchase order in September 2026; about $1.0 million shipped by September 30, 2026.
- Remaining $3.6 million from that order is expected to ship in Q1 and Q2 fiscal 2027; open purchase orders totaled $5.4 million as of Sept 30, 2026.
- CEO Dave Rosa said fiscal 2026 product orders rose 24.2%, with growth drivers including trigeminal neuralgia system commercialization and international expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026106677/0001213900-26-106677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026106677/ea0307577-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-106677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer